For laboratory & research use only. Not for human consumption.
Sexual Health & Wellness

Original PT-141: Discovery & Research History

PT-141 (Bremelanotide) — how it was originally developed, and what it has been studied for since.

How PT-141 Was Discovered

PT-141 (bremelanotide) was developed by Palatin Technologies as a structural analog of Melanotan II, itself a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) originally studied for skin pigmentation. Researchers noticed Melanotan II's central nervous system effects on sexual arousal during that earlier research, which led Palatin to develop PT-141 specifically around melanocortin receptor activity relevant to sexual function rather than pigmentation.

PT-141 is a cyclic heptapeptide that acts primarily at MC4R, expressed in the hypothalamus and limbic system. Its proposed mechanism is central (via the nervous system), distinguishing it from the peripheral vasodilation mechanism used by drugs like sildenafil.

What PT-141 Has Been Studied For

Two identical Phase 3 trials known as RECONNECT enrolled premenopausal women with hypoactive sexual desire disorder (HSDD), finding statistically significant improvements in sexual desire and related distress compared to placebo. Based on this data, the FDA approved bremelanotide in June 2019 under the brand name Vyleesi.

  • Melanocortin receptor (MC3R/MC4R) pharmacology research
  • Central nervous system sexual arousal pathway research
  • Comparative research against peripherally-acting compounds

Read our Sexual Health & Wellness research overview →

See every peptide's discovery history →

Research Use Only Notice This page provides historical and educational context about how PT-141 was originally developed and what it has been studied for. It is not a claim about current regulatory approval, safety, or legal status in any market. Any PT-141 sourced through KYIN Peptides is sold strictly for laboratory research use by qualified professionals — not for human or animal use, and not intended for diagnostic, therapeutic, or consumption purposes.
FAQ

PT-141 discovery & history questions

Does PT-141's research history mean it's approved for a particular use?

No. This page describes how PT-141 was originally developed and what it has been studied for since — it is historical and educational context, not a claim about current regulatory approval, safety, or legal status anywhere. Any PT-141 sourced through KYIN Peptides is for laboratory research use only.

What has PT-141 been studied for in research?

PT-141 is studied for melanocortin receptor (MC3R/MC4R) activity in central nervous system sexual arousal research, and is FDA-approved as the pharmaceutical Vyleesi.

Interested in sourcing PT-141?

Not part of our standard catalogue, but available to order — contact us and we'll help you source it.